{"id":"https://genegraph.clinicalgenome.org/r/98575a3c-7a18-4941-8570-530a5d44edecv2.2","type":"EvidenceStrengthAssertion","dc:description":"*GNE* was first reported in relation to hereditary isolated macrothrombocytopenia in 2018 (Revel-Vilk et al, PMID: 30171045; Futterer et al, PMID: 29941673). Evidence supporting this gene-disease curation includes case-level data, segregation data, and experimental data. Twelve unique variants (missense, nonsense, frameshift) have been reported in humans. Variants in this gene have been reported in at least 10 probands in 7 publications. Variants in this gene segregated with disease in 8 additional family members. The gene disease relationship is supported by biochemical function experiments (PMID: 30171045). Of note, this gene has also been implicated in both *GNE* myopathy and sialuria, which are considered distinct from this isolated macrothrombocytopena. In summary, there is moderate evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship.\n\nThis gene-disease pair was originally evaluated by the HT GCEP on 08/29/2020. It was reevaluated on 05/25/2022. As a result of this reevaluation, the classification was upgraded to Moderate with the addition of new case-level evidence (PMIDs: 33217855, 33198675, 34858435, 33637881, 35052006).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/98575a3c-7a18-4941-8570-530a5d44edec","GCISnapshot":"https://genegraph.clinicalgenome.org/r/335d18ae-50ef-49a8-abb2-79799833b544","calculatedEvidenceStrength":"Moderate","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/335d18ae-50ef-49a8-abb2-79799833b544_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10028","date":"2023-09-14T16:38:38.707Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/335d18ae-50ef-49a8-abb2-79799833b544_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10028","date":"2022-05-25T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/335d18ae-50ef-49a8-abb2-79799833b544_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/335d18ae-50ef-49a8-abb2-79799833b544_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ad38301-a66e-407a-981c-eae462cd0290","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2fa4c1ca-5a29-4aae-946e-7020a89b35c1","type":"Finding","dc:description":"UPD-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (encoded by GNE), is a bifunctional enzyme that catalyzes the first two reactions in the sialylation pathway.  Sialic acid is ubiquitously expressed on hematopoetic cells.  It is well documented that desialyation of platelets shortens platelets lifespan by early clearance (PMID:8115995; 20729731).Patient platelet sialic acid levels were measured by flow cytometry and were found to be decreased compared to normal controls.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","rdfs:label":"Revel-Vilk - Biochemical Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/335d18ae-50ef-49a8-abb2-79799833b544_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/02b7c252-540c-44f9-9116-e16ee8ee929d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/02b7c252-540c-44f9-9116-e16ee8ee929d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29941673","rdfs:label":"III:5","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/06f16840-a0c2-4367-a96d-6d53b798af23","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.1246G>A (p.Gly416Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10605519"}},"detectionMethod":"Whole exome of the affected family member was completed using the SureSelect human All Exon 50Mb kit and sequenced on the HiSeq2000.  The sequence reads were aligned to the reference genome hg19.  All quality candidate variants were confirmed by Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"High immature platelet fraction","phenotypes":["obo:HP_0030746","obo:HP_0040185"],"previousTesting":true,"previousTestingDescription":"Clinical and laboratory data include family and personal history , physical examination, complete blood counts, and bone marrow evaluation.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/fd898bff-617c-45e3-8e5b-d491115b5eab_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29941673","allele":{"id":"https://genegraph.clinicalgenome.org/r/06f16840-a0c2-4367-a96d-6d53b798af23"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/fd898bff-617c-45e3-8e5b-d491115b5eab","type":"EvidenceLine","dc:description":"The homozygous missense variant, Gly416Arg, does not have functional data to support a damaging effect on the gene or gene product, however flow cytomtery assessment of the proband's platelets demonstrated that surface glycoproteins CD42b and CD41 fell outside of reference ranges and weak binding of fibrinogen to ADP, collagen-related peptide, and protease-activated receptor 1, suggesting global platelet dysfunction.","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fd898bff-617c-45e3-8e5b-d491115b5eab_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/9cf8fb6b-be99-433e-812e-7ac67589a2d0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9cf8fb6b-be99-433e-812e-7ac67589a2d0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34858435","rdfs:label":"Smolag - proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":17,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/639a9d31-70bd-4f0d-89f0-c4e5d1c00980","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.1259G>A (p.Arg420Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5056549"}},{"id":"https://genegraph.clinicalgenome.org/r/317ad611-1fb7-4a92-bfb7-aee0db7fb639","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.323_333del (p.Ile108ArgfsTer4)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573106149"}}],"detectionMethod":"Genomic DNA was purified from whole blood using Nextera DNA Flex library Preparation (Illumina). Sequencing was performed using the NovaSeq6000 platform.","firstTestingMethod":"Whole genome shotgun sequencing","phenotypeFreeText":"Significantly increased immature platelet fraction","phenotypes":["obo:HP_0001892","obo:HP_0001902","obo:HP_0001875","obo:HP_0011877","obo:HP_0001873"],"previousTesting":true,"previousTestingDescription":"Routine CBC's occurred throughout life due to low platelet counts. TEM revealed giant platelets. Bone marrow findings were unremarkable as was spleen size upon abdominal ultrasound.","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/3e7e2421-1b9b-48f2-9499-32cab931fe51_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34858435","allele":{"id":"https://genegraph.clinicalgenome.org/r/317ad611-1fb7-4a92-bfb7-aee0db7fb639"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/4d7de1df-d426-48df-84e4-7bbd8004c89b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34858435","allele":{"id":"https://genegraph.clinicalgenome.org/r/639a9d31-70bd-4f0d-89f0-c4e5d1c00980"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/4d7de1df-d426-48df-84e4-7bbd8004c89b","type":"EvidenceLine","dc:description":"The missense variant, c.1352G>A, p.R451Q (p.R420Q) does not have functional evidence to support it pathogenecity.  However, studies of sialic acid levels on the patients' platelets and leukocytes demonstrated a significant (~80%) reduction of sialic acid on platelets, granulocytes, lymphocytes, and monocytes. The minor allele frequency in the general population is 0.000007954.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d7de1df-d426-48df-84e4-7bbd8004c89b_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/3e7e2421-1b9b-48f2-9499-32cab931fe51","type":"EvidenceLine","dc:description":"The frameshift variant, c.416_426del, p.I139Rfs*4 (p.I108Rfs*4) is predicted to undergo NMD.  ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e7e2421-1b9b-48f2-9499-32cab931fe51_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/c3f649d7-2973-4937-8035-cbf2a1a9a769_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3f649d7-2973-4937-8035-cbf2a1a9a769","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33217855","rdfs:label":"Mekchay Pt 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":24,"allele":{"id":"https://genegraph.clinicalgenome.org/r/7b524df9-b7f3-4e36-8354-1de96b392921","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.1639G>A (p.Gly547Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373425912"}},"detectionMethod":"Whole Exome Sequencing (WES) was conducted using SureSelect Human All Exon V5 kit. The captured libraries were sequenced using Illumina HiSeq 4000. ","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Increased glycogen granules on EM","phenotypes":["obo:HP_0002239","obo:HP_0001902","obo:HP_0000978","obo:HP_0011877","obo:HP_0001873","obo:HP_0000132"],"previousTesting":true,"previousTestingDescription":"Inclusion criteria for the study included no previously normal platelet counts.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d2919fbc-2f72-4050-9e4c-d946536ef96c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33217855","allele":{"id":"https://genegraph.clinicalgenome.org/r/7b524df9-b7f3-4e36-8354-1de96b392921"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/d2919fbc-2f72-4050-9e4c-d946536ef96c","type":"EvidenceLine","dc:description":"The homozygous missense variant, c.1417G>A, p.G473S (G547S), does not have functional evidence supporting its pathogenicity, however flow cytometric studies of sialic acid expression demonstrated ~70% decrease as compared to wild type which specific for a disorder affecting GNE, a key enzyme of sialic acid biosynthesis.  The minor alle frequency in the general population is 0.000007953 (GnomAD).","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2919fbc-2f72-4050-9e4c-d946536ef96c_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/ee450c8a-52f7-4910-8e53-531b1e9c05eb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee450c8a-52f7-4910-8e53-531b1e9c05eb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33637881","rdfs:label":"Miskiewicz-Bujna - Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":16,"allele":{"id":"https://genegraph.clinicalgenome.org/r/28c82488-46ed-4438-b446-6b2f4739eabd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.2003C>T (p.Ser668Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373424635"}},"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"abnormal megakaryocytes; suppressed platelet production","phenotypes":["obo:HP_0001882","obo:HP_0001897","obo:HP_0001873","obo:HP_0031020"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6cdb20b9-16ff-4534-be6f-c33deaf5bb73_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33637881","allele":{"id":"https://genegraph.clinicalgenome.org/r/28c82488-46ed-4438-b446-6b2f4739eabd"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/6cdb20b9-16ff-4534-be6f-c33deaf5bb73","type":"EvidenceLine","dc:description":"The missense variant, c.2096C>T, p.S699F (p.S668F) does not have functional evidence to support its pathogenicity.  ","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6cdb20b9-16ff-4534-be6f-c33deaf5bb73_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/db0b26bd-63d5-4be9-9b28-609d3845d753_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db0b26bd-63d5-4be9-9b28-609d3845d753","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","rdfs:label":"P7","allele":{"id":"https://genegraph.clinicalgenome.org/r/ccfbcf79-2990-44c8-afc9-d5ce1a6dd62f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.1457T>C (p.Leu486Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/627242"}},"detectionMethod":"DNA was tested on the ThromboGenomics highthroughput sequencing (HTS) platform and analyzed using TG2 (the second generation panel with updated list of genes).","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0000132","obo:HP_0031386","obo:HP_0000978","obo:HP_0011888","obo:HP_0000421","obo:HP_0040185"],"previousTesting":true,"previousTestingDescription":"Clinical and laboratory data include family and personal history , physical examination, complete blood counts, and bone marrow evaluation.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b4d62e87-ef90-4bf6-94ec-b769e2c9ebd8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","allele":{"id":"https://genegraph.clinicalgenome.org/r/ccfbcf79-2990-44c8-afc9-d5ce1a6dd62f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/b4d62e87-ef90-4bf6-94ec-b769e2c9ebd8","type":"EvidenceLine","dc:description":"The homozygous missense variant, c.1457T>C, p.Leu486Pro does not have functional data to support a damaging effect on the gene or gene product.","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4d62e87-ef90-4bf6-94ec-b769e2c9ebd8_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/7c4abe52-e528-44f0-aa01-c8d124869f58_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7c4abe52-e528-44f0-aa01-c8d124869f58","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35052006","rdfs:label":"Ziegler - Proband","ageType":"AgeAtOnset","ageUnit":"Days","allele":[{"id":"https://genegraph.clinicalgenome.org/r/368cc764-fe6e-4a15-b31f-e3bea43154c2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.1250C>T (p.Thr417Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373428596"}},{"id":"https://genegraph.clinicalgenome.org/r/639a9d31-70bd-4f0d-89f0-c4e5d1c00980"}],"detectionMethod":"Nextera Rapid Custom Enrichment panel of 95 genes was tested and sequenced by MiSeq.","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0002170","obo:HP_0001873","obo:HP_0012233"],"previousTesting":true,"previousTestingDescription":"Comprehensive testing for inherited bleeding and platelet disorders was conducted without significant findingd. Testing for VWD and NAIT were both negative.  Testing for lupus antibodies were negative, while virus serology was borderline for rubella virus, parvovirus B19, varicella-zoster virus, and herpes simplex virus 1/2. Microbacteriological testing was negative, as was testing for endocrinopathies.  MRI and ultrasound was performed which did not detect vessel malformations, or heart defects. ","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/2bc2c712-ad7d-43c1-b3ab-aacb14f9b78e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35052006","allele":{"id":"https://genegraph.clinicalgenome.org/r/639a9d31-70bd-4f0d-89f0-c4e5d1c00980"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/af0ea3b8-9320-47e5-8655-09da17f9e399_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35052006","allele":{"id":"https://genegraph.clinicalgenome.org/r/368cc764-fe6e-4a15-b31f-e3bea43154c2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/2bc2c712-ad7d-43c1-b3ab-aacb14f9b78e","type":"EvidenceLine","dc:description":"The missense variant, c.1259G>A, p.R420Q does not have functional evidence to support its pathogenicity, however, a lectin array was performed using patient platelet lysates.  Significantly reduced alpha-2,3-sialic acid was noted.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2bc2c712-ad7d-43c1-b3ab-aacb14f9b78e_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/af0ea3b8-9320-47e5-8655-09da17f9e399","type":"EvidenceLine","dc:description":"The missense variant, c.1250C>T, p.T417M does not have functional evidence to support its pathogenicity, however, a lectin array was performed using patient platelet lysates.  Significantly reduced alpha-2,3-sialic acid was noted.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/af0ea3b8-9320-47e5-8655-09da17f9e399_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/335d18ae-50ef-49a8-abb2-79799833b544_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/deb7638a-9315-4e94-9876-722d3cc8a9ca_proband_segregation","type":"FamilyCosegregation","dc:description":"Cannot use LOD because there are not enough segregations","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","rdfs:label":"Revel-Vilk-II","estimatedLodScore":1.7,"family":{"id":"https://genegraph.clinicalgenome.org/r/deb7638a-9315-4e94-9876-722d3cc8a9ca","type":"Family","rdfs:label":"Revel-Vilk-II","member":{"id":"https://genegraph.clinicalgenome.org/r/db0b26bd-63d5-4be9-9b28-609d3845d753"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":4,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0031386","obo:HP_0000978","obo:HP_0040185","obo:HP_0000132","obo:HP_0011888","obo:HP_0000421"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/db0b26bd-63d5-4be9-9b28-609d3845d753"}},{"id":"https://genegraph.clinicalgenome.org/r/8a66040f-0d4a-4050-aab2-5debfbd05c38_proband_segregation","type":"FamilyCosegregation","dc:description":"Cannot use LOD because there are not enough segregations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","rdfs:label":"Revel-Vilk-III","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/8a66040f-0d4a-4050-aab2-5debfbd05c38","type":"Family","rdfs:label":"Revel-Vilk-III","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/543a0360-581f-4c40-9ebf-8c998316398d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","rdfs:label":"P9","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":11,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/1271a3d6-6dc0-4482-bb45-8fbe40be6a25","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.1556A>G (p.Asn519Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/556674"}},{"id":"https://genegraph.clinicalgenome.org/r/7d6cc523-8960-4d6b-8056-5ab2bc36289c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001190388.2(GNE):c.292C>T (p.His98Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373418556"}}],"detectionMethod":"WGS performed by Illumina Inc using a TruSeq DNA PCR-free protocol such that at least 95% of the reference was covered at >15x.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Whole genome shotgun sequencing","phenotypeFreeText":"platelet transfusions","phenotypes":["obo:HP_0040185","obo:HP_0000421","obo:HP_0000978"],"previousTesting":true,"previousTestingDescription":"Clinical and laboratory data include family and personal history , physical examination, complete blood counts.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/00d5d4e1-7099-4e92-a504-a2d6196816cb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","allele":{"id":"https://genegraph.clinicalgenome.org/r/7d6cc523-8960-4d6b-8056-5ab2bc36289c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/d4828614-7f00-4ac6-8ca8-7489458b2f6a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","allele":{"id":"https://genegraph.clinicalgenome.org/r/1271a3d6-6dc0-4482-bb45-8fbe40be6a25"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"meetsInclusionCriteria":false,"phenotypeFreeText":"platelet transfusions","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0000421","obo:HP_0000978","obo:HP_0040185"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/543a0360-581f-4c40-9ebf-8c998316398d"}},{"id":"https://genegraph.clinicalgenome.org/r/38fdca5e-d82d-402d-9698-b4b8078776de_proband_segregation","type":"FamilyCosegregation","dc:description":"LOD score cannot be used because there are less than 3 affected individuals in this family.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29941673","rdfs:label":"Futterer","estimatedLodScore":1.48,"family":{"id":"https://genegraph.clinicalgenome.org/r/38fdca5e-d82d-402d-9698-b4b8078776de","type":"Family","rdfs:label":"Futterer","member":{"id":"https://genegraph.clinicalgenome.org/r/02b7c252-540c-44f9-9116-e16ee8ee929d"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"Hight immature platelet fraction","phenotypeNegativeAlleleNegative":7,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0040185","proband":{"id":"https://genegraph.clinicalgenome.org/r/02b7c252-540c-44f9-9116-e16ee8ee929d"}},{"id":"https://genegraph.clinicalgenome.org/r/e3e9c67c-e7c1-4c4f-96c2-7c0746870780_proband_segregation","type":"FamilyCosegregation","dc:description":"Whole exome sequencing was used to determine the causative variants in this family.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","rdfs:label":"Revel-Vilk-I","estimatedLodScore":5.03,"family":{"id":"https://genegraph.clinicalgenome.org/r/e3e9c67c-e7c1-4c4f-96c2-7c0746870780","type":"Family","rdfs:label":"Revel-Vilk-I","member":{"id":"https://genegraph.clinicalgenome.org/r/9a81ce61-3381-4fe7-b57b-7e4570b00be0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","rdfs:label":"P1","allele":{"id":"https://genegraph.clinicalgenome.org/r/1cb4f4a0-82c3-48cd-ab0f-b0df1f484313","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001190388.2(GNE):c.1246_1247delinsTT (p.Gly416Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139532203"}},"detectionMethod":"Single nucleotide polymorphism (SNP) analysis was performed on DNA samples using AffymetrixÂ® CytoScan HD Array.  Whole exome sequencing was performed, analyzed and filtered which yielded coverage of >100X.  Candidate variants were confirmed by Sanger sequencing.","firstTestingMethod":"Other","phenotypeFreeText":"hemorrhagic corpus luteum","phenotypes":["obo:HP_0001873","obo:HP_0000978","obo:HP_0040185","obo:HP_0000132","obo:HP_0000421"],"previousTesting":true,"previousTestingDescription":"Clinical and laboratory data include family and personal history , physical examination, complete blood counts.","secondTestingMethod":"Exome sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a40bd92c-0470-4df3-ae5f-2e5fd96865ee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30171045","allele":{"id":"https://genegraph.clinicalgenome.org/r/1cb4f4a0-82c3-48cd-ab0f-b0df1f484313"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"hemorrhagic corpus luteum","phenotypeNegativeAlleleNegative":21,"phenotypePositiveAllelePositive":5,"phenotypes":["obo:HP_0000421","obo:HP_0040185","obo:HP_0000978","obo:HP_0000132","obo:HP_0001873"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/9a81ce61-3381-4fe7-b57b-7e4570b00be0"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/f09628ee-2b4a-420e-b43c-d1ff42b948ba_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f09628ee-2b4a-420e-b43c-d1ff42b948ba","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33198675","rdfs:label":"Li - Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":22,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/b216cf92-195f-407c-a57a-fec7b8b92856","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.1258C>T (p.Arg420Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5056550"}},{"id":"https://genegraph.clinicalgenome.org/r/8216db0c-edc0-4cc6-a43b-3e36983a3ef8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005476.7(GNE):c.1237G>T (p.Asp413Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373428665"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"hindered maturation of megakaryocytes","phenotypes":["obo:HP_0011877","obo:HP_0001903","obo:HP_0001873"],"previousTesting":false,"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/acf1282a-f680-4bc3-ad77-5b0ad0c4073f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33198675","allele":{"id":"https://genegraph.clinicalgenome.org/r/b216cf92-195f-407c-a57a-fec7b8b92856"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/5cff990b-9293-4809-b907-0ec44d37aba2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33198675","allele":{"id":"https://genegraph.clinicalgenome.org/r/8216db0c-edc0-4cc6-a43b-3e36983a3ef8"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/5cff990b-9293-4809-b907-0ec44d37aba2","type":"EvidenceLine","dc:description":"The missense variant, c.1330G>T, p.D444Y (p.D413Y) does not not functional evidence supporting pathogenicity. The minor allele frequency in the general population is 0.000003977.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5cff990b-9293-4809-b907-0ec44d37aba2_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/acf1282a-f680-4bc3-ad77-5b0ad0c4073f","type":"EvidenceLine","dc:description":"The nonsense variant, c.1351C>T, p.R451* (p.R420*) removes 40% of GNE and is expected to undergo NMD. The minor allele frequency in the general population is 0.00001591.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/acf1282a-f680-4bc3-ad77-5b0ad0c4073f_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/9a81ce61-3381-4fe7-b57b-7e4570b00be0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a81ce61-3381-4fe7-b57b-7e4570b00be0"},{"id":"https://genegraph.clinicalgenome.org/r/a40bd92c-0470-4df3-ae5f-2e5fd96865ee","type":"EvidenceLine","dc:description":"The homozygous variant c.1516_1517delinsTT, p.Gly475Phe has supporting evidence to demonstrate its damaging effect. Affected individuals have low expression of CD42b suggesting loss of the glycocalicin domain. Patients platelets showed decreased levels of sialyation compared to controls. Protein analysis of patient platelet extracts using mass spectrometry demonstrate downregulation of platelet activation, adhesion, and would healing pathways.","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a40bd92c-0470-4df3-ae5f-2e5fd96865ee_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/543a0360-581f-4c40-9ebf-8c998316398d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/543a0360-581f-4c40-9ebf-8c998316398d"},{"id":"https://genegraph.clinicalgenome.org/r/d4828614-7f00-4ac6-8ca8-7489458b2f6a","type":"EvidenceLine","dc:description":"The missense variants, c.1556A>G, p.Asn519S and c.469C>T, p.His157Tyr are confirmed to be in trans. Studies of this proband's cells show decreased levels of sialyation compared to controls and low expression of CD42b suggesting loss of the glycocalicin domain.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d4828614-7f00-4ac6-8ca8-7489458b2f6a_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/d4828614-7f00-4ac6-8ca8-7489458b2f6a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The missense variants, c.1556A>G, p.Asn519S and c.469C>T, p.His157Tyr are confirmed to be in trans. Studies of this proband's cells show decreased levels of sialyation compared to controls and low expression of CD42b suggesting loss of the glycocalicin domain.","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/00d5d4e1-7099-4e92-a504-a2d6196816cb","type":"EvidenceLine","dc:description":"The missense variants, c.1556A>G, p.Asn519S and c.469C>T, p.His157Tyr are confirmed to be in trans. Studies of this proband's cells show decreased levels of sialyation compared to controls and low expression of CD42b suggesting loss of the glycocalicin domain.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00d5d4e1-7099-4e92-a504-a2d6196816cb_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":7.6}],"evidenceStrength":"Moderate","sequence":6855,"specifiedBy":"GeneValidityCriteria9","strengthScore":8.1,"subject":{"id":"https://genegraph.clinicalgenome.org/r/KNXQ-_OKzyE","type":"GeneValidityProposition","disease":"obo:MONDO_0031447","gene":"hgnc:23657","modeOfInheritance":"obo:HP_0000007"},"version":"2.2","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_335d18ae-50ef-49a8-abb2-79799833b544-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}